OPPM
SIOX

Opus Point Partners Management’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Opus Point Partners Management’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,178
Closed -$404K – 69
2017
Q2 		$404K Hold
2,178
– – 0.37% 50
2017
Q1 		$260K Buy
+2,178
New +$228K 0.19% 65
2016
Q4 		– Sell
-1,856
Closed -$208K – 63
2016
Q3 		$208K Buy
1,856
+182
+11% +$21.8K 0.12% 44
2016
Q2 		$172K Sell
1,674
-1,628
-49% -$163K 0.17% 43
2016
Q1 		$303K Buy
3,302
+945
+40% +$101K 0.23% 51
2015
Q4 		$340K Sell
2,357
-1,483
-39% -$193K 0.22% 53
2015
Q3 		$397K Buy
+3,840
New +$450K 0.22% 46

Other funds holding SIOX

QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
IA
IPL Advisers New York $158M AUM 18.16% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Opus Point Partners Management's SIOX Position: Q3 2017 in Review

Opus Point Partners Management sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q3 2017, closing a stake of 2,178 shares — an estimated $404K sold.

Opus Point Partners Management first reported a position in SIOX in Q3 2015 and held it in 7 quarters. The position peaked at $404K in Q2 2017. 114 funds tracked by Wall St. Rank hold SIOX as of Q3 2017.

  • Opus Point Partners Management reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • Opus Point Partners Management sold 2,178 Sio Gene Therapies Inc. Common Stock shares in Q3 2017, an estimated $404K.
  • Opus Point Partners Management first reported a position in Sio Gene Therapies Inc. Common Stock in Q3 2015 and held it in 7 quarters.
  • Opus Point Partners Management's Sio Gene Therapies Inc. Common Stock position peaked at $404K in Q2 2017.
  • 114 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q3 2017.

Based on Opus Point Partners Management's 13F filing for Q3 2017, filed 14 Nov 2017.